Shares of Tenax Therapeutics, Inc. surged 27.84% on Tuesday following the disclosure that a significant shareholder made $1.81 million in open-market buys.
Tenax Therapeutics · NASDAQ close · August 25, 2026, 16:00 EDT
Tuesday’s 27.84% rally recovered only a fraction of the post-trial loss. The stock remains 82.4% below August 7.
| Metric | Value |
|---|---|
| Average cost | $1.7684 |
| Cost | $1.814M |
| Value at close | $2.431M |
| Paper gain | +$617K / +34.0% |
| Reported holding | 4,853,818 shares |
The filer is a 10% owner/director, not a Tenax operating executive. Filing published August 24, 2026, 18:13 EDT.
| Measure | Result |
|---|---|
| 6-minute walk distance | Primary endpoint missed |
| KCCQ symptom score | Key secondary missed |
| Lower-walk subgroup | +26.3m; nominal p=0.0112 |
| NT-proBNP | 49% greater reduction |
| RV systolic pressure | −3.5 mmHg |
| Serious adverse events | 10.8% vs 10.7% |
| Q2 2026 metric | Value | Comparison |
|---|---|---|
| Cash, June 30 | $117.98M | Runway through Q2 2028 |
| Net loss | $17.80M | $10.85M prior year |
| R&D | $12.85M | $6.12M prior year |
| Operating expense | $18.78M | $11.79M prior year |
| Shares at June 30 | 31.9M | 9.3M at Dec. 31 |
| Firm | August action | Target | Upside from $2.37 |
|---|---|---|---|
| Canaccord Genuity | Buy maintained | $4 from $35 | 68.8% |
| Guggenheim | Buy maintained | $4 from $40 | 68.8% |
| Chardan | Buy → Neutral | $5 from $27 | 111.0% |
| Evercore ISI | Outperform → In-Line | $5 from $39 | 111.0% |
Targets can lag rapidly changing biotechnology probabilities. Actions shown are dated August 11, 2026.
Market data: Public and Benzinga, regular-session close at August 25, 2026, 16:00 EDT. Insider data: Form 4 published August 24. Trial and event data: Tenax releases. Financial data: Tenax Form 10-Q for June 30, 2026. Equity value is derived from 37.42 million shares at $2.37 and may differ from vendor market-cap fields.
